Evidence map›Paper›PMID 29255624›Full record

ArticleFuture science OA2018

Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies.

Mostafa Mm El-Miligy, Samia M Rida, Fawzia A Ashour, Mona H Badr, Ehab M El-Bassiony, Maha A El-Demellawy, Ashraf M Omar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Mostafa Mm El-MiligyPharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Samia M RidaPharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Fawzia A AshourPharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Mona H BadrPharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Ehab M El-BassionyPharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Maha A El-DemellawyMedical Biotechnology Department, Genetic Engineering & Biotechnology Research Institute, City for Scientific Research & Technology Applications, Alexandria, Egypt.
Ashraf M OmarMedical Biotechnology Department, Genetic Engineering & Biotechnology Research Institute, City for Scientific Research & Technology Applications, Alexandria, Egypt.
Alexandria University · EGCity of Scientific Research and Technological Applications · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimSimultaneous inhibition of hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) may enhance anti-HCV effects and reduce resistance and side effects. RESULTS/METHODOLOGY: Novel hybrid derivatives were designed and synthesized to exhibit dual activity against HCV and its associated major complication, HCC. The synthesized compounds were screened for their potential activity against HCV and HCC. Compounds

conclusionCompounds

Indexed as

benzimidazolebenzofurandockingHCC inhibitorsHCV inhibitorsthiazolidinone

Identifiers

PMID29255624
PMCPMC5729604
OpenAlexW2766934373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.